Baricitinib
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19. Phase 3.
| Trivial name | INCB028050, LY3009104 |
| Catalog Number | S2851 |
| Molecular Formula | C16H17N7O2S |
| CAS# | 1187594-09-7 |
| Inchi | InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) |
| Inchi Key | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| SMILES | CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/baricitinib-ly3009104.html |
| Additional Information | https://file.selleck.cn/downloads/struct/Baricitinib-chemical-structure-s2851.gif |